Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Glow Stack Alternatives 2026: Peptide Comparison

Thymalin Thymic bioregulation, T-cell differentiation 5–10mg every 5–7 days −20°C lyophilised, 2–8°C reconstituted Immune senescence, tissue regeneration research Most reliable for thymic function studies. Established peptide sequence with decades of Soviet-er

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Thymalin
  • Thymic bioregulation, T-cell differentiation
  • 5–10mg every 5–7 days
  • −20°C lyophilised, 2–8°C reconstituted
  • Immune senescence, tissue regeneration research
  • Most reliable for thymic function studies. Established peptide sequence with decades of Soviet-era research foundation
  • MK-677
  • Growth hormone secretagogue (ghrelin mimetic)
  • 10–25mg daily oral
  • Room temperature stable (oral form)
  • GH pulsatility, lean mass, bone density research
  • Non-injectable convenience with consistent IGF-1 elevation in 24-month trials. Rare for oral peptide mimetics
  • Cerebrolysin
  • Neurotrophic peptide complex, BDNF activation
  • 5–30ml IV over 10–20 sessions
  • 2–8°C (aqueous solution)
  • Neuroplasticity, stroke recovery, cognitive research
  • Gold standard for neurotrophic peptide research. Published efficacy in 1,500+ patient trials across neurological conditions
  • Dihexa
  • HGF/c-Met pathway agonist, synaptogenesis
  • 1–5mg daily (nanomolar potency)
  • Synapse formation, cognitive enhancement research
  • Seven orders of magnitude more potent than BDNF at promoting synaptogenesis. Exceptional for targeted neuroplasticity studies
  • Survodutide
  • Dual GLP-1/glucagon receptor agonist
  • 2.4–4.8mg weekly subcutaneous
  • 2–8°C reconstituted, stable 28 days
  • Metabolic research, fat oxidation studies
  • Phase 2 trials showed 12.8% body weight reduction at 48 weeks. Dual-agonist mechanism compounds GLP-1 satiety with glucagon thermogenesis
  • Mazdutide
  • GLP-1/glucagon dual agonist
  • 3–6mg weekly subcutaneous
  • 2–8°C reconstituted
  • Metabolic pathway research, energy expenditure
  • Similar dual-receptor targeting to survodutide with slightly different receptor affinity profile. Useful for comparative mechanism studies